Genentech Gets Non-Hodgkin’s Lymphoma Candidate With Seattle Genetics Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
SGN-40 will be examined for potential use with and without Rituxan.
You may also be interested in...
Seattle Genetics CEO Clay Siegall: An Interview With “The Pink Sheet” DAILY (Part 1 Of 2)
Biotech chief exec sits down to talk about the comprehensive development program for SGN-40 in cancer and partnering with Genentech.
Seattle Genetics CEO Clay Siegall: An Interview With “The Pink Sheet” DAILY (Part 1 Of 2)
Biotech chief exec sits down to talk about the comprehensive development program for SGN-40 in cancer and partnering with Genentech.
Seattle Genetics Seeks To “Change The Treatment Paradigm” For Non-Hodgkin’s Lymphoma
Registration path for SGN-40, partnered with Genentech, could be through front-line treatment of aggressive NHL.